SEC Filing Summary: Prima BioMed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima BioMed Ltd, a foreign private issuer headquartered in Sydney, Australia, on June 19, 2013. The filing serves to report specific corporate governance updates rather than financial performance results.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report contains no financial statements or operational metrics.
Material Changes
The material change disclosed in this filing relates to corporate governance. The registrant submitted three separate notices (Exhibits 99.1, 99.2, and 99.3) regarding changes in Directors' interests under Appendix 3Y.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of director interest changes.
Key Facts for Investor Verification
- The filing date is June 19, 2013.
- The report discloses changes in the shareholding or interest of the company's directors.
- Three distinct notices of change were filed as exhibits.
- No financial performance data is included in this specific submission.